Hypereosinophilic syndrome · 10 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Alemtuzumab monotherapy Variant #01 | — | R 132 218 | 7d | ~15.0 mo | — | ~66 | ~R 8 726 355 PFS proxy · indirect | — |
Cladribine and Cytarabine Variant #01 | — | R 84 432 | 21d | — | — | — | — | — |
Ruxolitinib monotherapy Variant #01 | — | R 60 650 | 28d | — | — | — | — | 2 |
Benralizumab monotherapy Variant #01 | — | R 31 983 | 28d | — | — | — | — | — |
Nilotinib monotherapy Variant #01 | — | R 27 206 | 28d | — | — | — | — | — |
Imatinib monotherapy Variant #17 | — | R 27 014 | 30d | ~20.0 mo | ~53.0 mo | ~21 | ~R 567 284 PFS proxy · indirect | 8 |
Hydroxyurea monotherapy Variant #01 | — | R 278 | 28d | — | ~243.6 mo | — | — | — |
Peginterferon alfa-2a monotherapy N/A - secondary systemic drug | — | R 7 | 7d | — | — | — | — | — |
Placebo Partial | — | — | — | ~4.2 mo | ~8.0 mo | — | — | 145 |
Mepolizumab monotherapy Variant #01 Partial | — | — | 21d | — | — | — | — | — |
10 of 10 regimens shown